Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $1.2 million.

  • Arcturus Therapeutics Holdings' Cash from Financing Activities rose 7676.77% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 11366.93%. This contributed to the annual value of $5.4 million for FY2024, which is 12249.35% up from last year.
  • Arcturus Therapeutics Holdings' Cash from Financing Activities amounted to $1.2 million in Q3 2025, which was up 7676.77% from -$14.7 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' Cash from Financing Activities' 5-year high stood at $47.0 million during Q1 2021, with a 5-year trough of -$27.4 million in Q1 2023.
  • In the last 5 years, Arcturus Therapeutics Holdings' Cash from Financing Activities had a median value of $257000.0 in 2022 and averaged $1.5 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Cash from Financing Activities surged by 3974067.8% in 2021 and then plummeted by 824404.76% in 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash from Financing Activities (Quarter) stood at $230000.0 in 2021, then plummeted by 1070.43% to -$2.2 million in 2022, then plummeted by 735.89% to -$18.7 million in 2023, then skyrocketed by 100.72% to $134000.0 in 2024, then soared by 814.18% to $1.2 million in 2025.
  • Its Cash from Financing Activities was $1.2 million in Q3 2025, compared to -$14.7 million in Q2 2025 and $15.2 million in Q1 2025.